Table 1: Summarizes all the large trials evaluating the use of exemestane in the adjuvant, metastatic, and preventative settings.
Study | Intervention |
Adjuvant | |
Morden JP, et al. [4] | Exemestane after 2 to 3 years of tamoxifen |
Placido SD, et al. [5] | Anastrozole vs. Exemestane vs. Letrozole upfront or after 2 years of tamoxifen |
Pagani O, et al. [8] | Exemestane plus ovarian suppression vs. Tamoxifen plus ovarian suppression |
Goss PE, et al. [13] | Exemestane vs. Anastrozole |
Derks MG, et al. [7] | Tamoxifen and Exemestane switch therapy vs. Exemestane alone |
Metastatic | |
Campos SM, et al. [9] | Exemestane vs. Anastrozole |
Beresford M, et al. [10] | Systematic review |
Baselga J, et al. [11] | Exemestane and Everolimus vs. Exemestane and Placebo |
Prevention | |
Goss PE, et al. [13] | Exemestane vs. Placebo |